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The United Kingdom (UK) added rotavirus (RV) vac-
cine (Rotarix GlaxoSmithKline) to the national vaccine 
schedule in July 2013. During the 2012–2014 rotavi-
rus seasons, children presenting to the Bristol Royal 
Hospital for Children Emergency Department with 
gastroenteritis symptoms had stool virology analy-
sis (real-time PCR) and clinical outcome recorded. 
Nosocomial cases were identified as patients with 
non-gastroenteritis diagnosis testing positive for rota-
virus > 48h after admission. In comparison to average 
pre-vaccine seasons, in the first year after vaccine 
introduction there were 48% fewer attendances diag-
nosed with gastroenteritis, 53% reduction in gastroen-
teritis admissions and a total saving of 330 bed-days 
occupancy. There was an overall reduction in number 
of rotavirus-positive stool samples with 94% reduction 
in children aged under one year and a 65% reduction 
in those too old to have been vaccinated. In the first 
year after the introduction of universal vaccination 
against rotavirus we observed a profound reduction in 
gastroenteritis presentations and admissions with a 
substantial possible herd effect seen in older children. 
Extrapolating these findings to the UK population we 
estimate secondary healthcare savings in the first year 
of ca £7.5 (€10.5) million. Ongoing surveillance will be 
required to determine the long-term impact of the RV 
immunisation programme.
Introduction
Acute gastroenteritis is one of the commonest paediat-
ric presenting complaints with the predominant cause 
being rotavirus (RV). Almost all children will have suf-
fered from RV gastroenteritis by the time they are five 
years old. Worldwide, RV is estimated to be responsi-
ble for more than 450,000 deaths in children every year 
[1] although with good nutritional status and access to 
medical care, death due to RV infection is exceptionally 
rare. In Bristol, as in the whole of the United Kingdom 
(UK), it is a highly seasonal infection occurring in 
annual epidemics in the late winter and early spring, 
although in tropical regions it persists year-round [2]. 
RV is a highly infectious organism, able to spread even 
in countries with high standards of hygiene. The only 
effective control strategy is vaccination [3]. The World 
Health Organization has recommended that all coun-
tries should include a vaccine against RV in their child-
hood schedules [4]. As of March 2015, only 12 of the 75 
countries to have introduced RV vaccination into their 
primary infant schedules were in Europe [5].
A 2007 health economic analysis estimated that if the 
vaccine could be purchased for a favourable price, 
RV vaccination could be cost-effective in the UK [6,7]. 
Although the UK has been at the forefront of universal 
childhood programmes using meningococcus group 
C conjugate and more recently live attenuated influ-
enza vaccines, vaccination against a disease that is 
extremely common but rarely leads to death or long-
term morbidity required a different paradigm and it 
was not until July 2013 that RV immunisation was intro-
duced into the routine childhood vaccine schedule at 
two and three months of age [8]. With an upper age 
limit of 24 weeks placed on the last dose of vaccine 
due to the reported association with intussusception, 
a catch-up campaign was not possible. It is now impor-
tant to evaluate the impact of this measure on the bur-
den of children’s illness and to evaluate whether the 
£20 (€28) million annual healthcare saving predicted 
by the Department of Health will be realised [9].
Methods
Bristol Royal Hospital for Children is the only hospi-
tal admitting children in Bristol and serves a popula-
tion of ca 55,000 children under the age of five years. 
Regardless of referral source, all patients are first seen 
in the paediatric emergency department. Since late 
February 2012 we have carried out routine surveillance 
2 www.eurosurveillance.org
of attendances with symptoms of gastroenteritis during 
successive RV seasons (weeks 1–27). All children <  18 
years presenting to the emergency department with 
symptoms of gastroenteritis (> 2 loose stools and/or > 1 
episode of forceful vomiting in the last 24 hours) had a 
standardised assessment (Vesikari score) [10] and had 
routine screening for viral gastroenteritis pathogens. 
Samples were tested for rotavirus and a panel of other 
gastroenteritis viruses using multiplex PCR. Patients’ 
clinical diagnosis was identified though note review 
and use of clinical coding. As enhanced surveillance 
started in late February 2012, data for weeks 1–7 of 
the 2012 epidemic were retrospectively obtained from 
a database of hospital records with coded diagnoses. 
Inpatient bed occupancy was calculated in hours from 
time of admission to time of hospital discharge. As 
not all patients were able to provide a stool sample, 
the proportion of all gastroenteritis attendances and 
admissions that were caused by rotavirus was esti-
mated from the proportion of samples received over the 
same time period that were confirmed to be rotavirus 
positive. Similarly, the proportion of positive results 
from stool samples received from children of different 
ages was used to estimate the overall age distribution 
of rotavirus cases.
Our strict hospital infection control policy meant that 
any patient who developed gastroenteritis while admit-
ted was tested for viral causes. By linking all positive 
stool results from our laboratory to admission date 
Figure 1
Distribution of all-cause gastroenteritis attendances, 
fortnightly totals, Bristol Royal Hospital for Children, 
United Kingdom, 2012–2014 
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Shaded area represents proportion estimated to be caused by 
rotavirus.
Figure 2
Distribution of all-cause gastroenteritis admissions, 
fortnightly totals, Bristol Royal Hospital for Children, 
United Kingdom, 2012–2014 
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and diagnosis, any later samples from admitted gas-
troenteritis patients could be included and patients 
admitted with a non-gastroenteritis diagnosis who 
tested positive for RV more than 48 hours after their 
admission could be retrospectively identified as noso-
comial infection. By definition these patients were not 
included in the analysis of the attendance or admitted 
cohorts.
In the UK, hospitals are paid according to an annu-
ally negotiated tariff based on the coded discharge 
diagnoses for an episode of care. From the 2013/2014 
National Health Service tariffs [11] the cost of an emer-
gency department attendance (VB09Z) was £96 (€135), 
and short-term viral gastroenteritis admission (PA21B) 
was £504 (€707). We used these to estimate the costs 
saved by the health service through RV vaccination.
Data were recorded in Microsoft Access. Data clean-
ing and statistical analysis was done using R [12]. 
Significance of annual changes in rates of attendance 
and admission were assessed using negative binomial 
regression model using year as a cofactor. Mann–
Whitney U test was used to compare age distributions 
and chi-squared test for proportions.
As this project involved analysis of the results of 
non-invasive standard clinical investigation and 
anonymised routine clinical data, this work was 
assessed as being a service evaluation by University 
Hospitals Bristol NHS Foundation Trust, with no ethical 
review or informed consent for research required.
Results
All cause gastroenteritis
In total, during the three rotavirus seasons there were 
3,410 emergency department attendances with median 
age 18 months (interquartile range (IQR): 9–42; range: 
0–202) and 722 admissions with median age 17 
months (IQR: 9–43; range: 0–202). Between 2012 and 
2013 there was significant variation in the number of 
all-cause gastroenteritis attendances (p < 0.001) but 
not in the proportion admitted (p = 0.7). In 2014 there 
was a 48% reduction in attendances (p < 0.001) and 
a 53% reduction in admissions (p < 0.001) compared 
with the mean in the pre-vaccine years 2012 and 2013. 
There was a 67–71% (p < 0.001) reduction in the total 
number of bed days occupied: equating to 1.7–2 fewer 
occupied beds in the hospital every day during the 
six-month period examined (Table 1). Median age of 
attendance rose significantly in the winter following 
vaccine introduction (Table 2) (p < 0.05). There was no 
significant difference in length of admission.
Figure 1 compares the fortnightly total numbers of 
attendances to the emergency department with gas-
troenteritis symptoms, demonstrating the onset of the 
gastroenteritis season for the three years of the study. 
Pre-vaccine rates of gastroenteritis attendance peaked 
in week 7 of 2012 and week 15 of 2013, while in 2014 
the seasonal epidemic was attenuated with a possible 
peak between weeks 8 to 10. Figure 2 demonstrates 
the corresponding number of patients admitted with 
gastroenteritis per fortnight during the study.
The age distributions of cases for the three years show 
that after vaccine introduction there were reductions 
in number of attendances (Figure 3) and admissions 
(Figure 4) across all age groups and not just in the 
infants under the age of one that would have been eli-
gible for the vaccine.
Rotavirus gastroenteritis
During the surveillance period samples were obtained 
from 35%, 30% and 30% of gastroenteritis attendances 
with diarrhoea in the three respective seasons. In 2012 
and 2013, 54% and 65% of these were positive for RV; 
Figure 3
Age distribution of all-cause gastroenteritis attendances 
< 18 years of age, Bristol Royal Hospital for Children, 
United Kingdom, 2012–2014 
0
25
50
75
100
125
150
175
200
225
250
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102108 114 120
Age in months
Nu
m
be
r o
f a
tte
nd
an
ce
s
0
25
50
75
100
125
150
175
200
225
250
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102108 114 120
Age in months
Nu
m
be
r o
f a
tte
nd
an
ce
s
0
25
50
75
100
125
150
175
200
225
250
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102108 114 120
Age in months
Nu
m
be
r o
f a
tte
nd
an
ce
s
A. 2012 (n=1,464) 
B. 2013 (n=1,239) 
C. 2014 (n=706)
Only ages 0–120 months shown for scale. Shaded area represents 
proportion estimated to be caused by rotavirus.
4 www.eurosurveillance.org
in 2014 this proportion fell to 36% (p < 0.001) (Table 
3). Combining the age distributions of positive samples 
and the overall gastroenteritis attendance rates (Figure 
1) reveals that as well as a 94% drop in RV attendances 
among those less than 12 months of age, there was 
also a 67–70% reduction in those too old to have been 
vaccinated (1–4 years).
In children who were admitted with gastroenteritis, the 
proportions of RV positive samples per year were 59%, 
63% and 40%, respectively. The number of gastroen-
teritis admissions likely to be attributable to RV fell 
from 175 in 2012 and 180 in 2013 to 55 in 2014: a 69% 
reduction (p < 0.001).
We identified six cases of nosocomial RV transmission 
in 2014 compared with eight in 2012 and 15 in 2013 (p 
= 0.16).
Financial effects
Between the years 2012 and 2013 we calculated RV to 
be responsible for a mean of 14.5 ED attendances and 
3.3 admissions per 1,000 children under the age of five. 
In 2014 this fell to 4.6 attendances and 1 admission per 
1,000 children under five years of age. If this fall is due 
to RV vaccine use, extrapolating these findings to the 
national paediatric population under the age of five 
years [13] would equate to approximate first year reduc-
tions of 35,700 ED attendances and 8,120 admissions. 
Before one whole birth cohort had been protected, we 
calculate secondary care savings of ca £7.5 (€10.5) mil-
lion in the first year of implementation.
Discussion
This is the first report of RV vaccine impact in the UK. 
This early evidence points to direct as well as possible 
indirect effects of this new immunisation programme 
2012 a 2013 2014 Change  2012 to 2014
Change  
2013 to 2014)
All-cause gastroenteritis
Attendances 1,464 1,239 706 -52% (p < 0.001) -43% (p < 0.001)
Admissions 297 288 137 -54% (p < 0.001) -52% (p < 0.001)
Bed days occupied 506 450 148 -71%( p < 0.001) -67% (p < 0.001)
Table 1
Number of cases of all-cause gastroenteritis aged < 18 years seen, Bristol Royal Hospital for Children, United Kingdom, 
January–July 2012–2014 (n=3,409)
a In 2012, 511 attendances and 114 admissions were identified through retrospective coding.
All-cause gastroenteritis 2012 2013 2014
Median age of
Attendance 17 months (IQR: 9–41) (p < 0.001)
17 months (IQR: 9–36) 
(p < 0.001) 23 months (IQR: 11–57)
Admission 18 months (IQR: 9–59) (p = 0.79)
15 months (IQR: 9–32) 
(p = 0.008) 20 months (IQR: 9–46)
Length of admission 16 hours (IQR: 6–39) (p = 0.34)
16 hours (IQR: 6–30) 
(p = 0.29) 14 hours (IQR: 6–25)
Table 2
Comparing age at attendance or admission and length of admission for all-cause gastroenteritis < 18 years, Bristol Royal 
Hospital for Children, United Kingdom, 2012–2014 (n=3,409)
IQR: interquartile range.
p values describe significance of differences in comparison to 2014.
Jan Feb Mar Apr May Jun
Total number 
of positive 
samples
Number of 
positive < 1 
year old
Number of 
positive > 1–4 
years old
Total 
number of 
samples
2012 1 (8%) 29 (57%) 78 (76%) 35 (66%) 6 (25%) 2 (8%) 151 (54%) 72 (48%) 77 (51%) 279
2013 4 (31%) 19 (56%) 86 (77%) 52 (69%) 19 (56%) 5 (26%) 185 (64%) 88 (48%) 92 (47%) 286
2014 4 (44%) 8 (35%) 13 (43%) 5 (25%) 6 (33%) 4 (33%) 40 (35%) 4 (10%) 35 (88%) 112
Table 3
Number of rotavirus positive samples and percentage testing positive by month in children < age of 18 years, Bristol Royal 
Hospital for Children, 2012–2014 (n=677)
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and suggests that optimistic predictions of significant 
impacts upon hospital emergency department and 
inpatient workloads during the peak winter period may 
have been well founded.
It is important to have clear baseline data against which 
to assess the impact of any intervention. Although we 
have only two years of data before vaccine introduc-
tion, our single site study has the advantage of con-
sistent sample collection methods with no change in 
testing behaviour throughout. In a vaccine probe study 
of this kind [14], using acute gastroenteritis attend-
ances may be less specific but is more sensitive than 
restricting analysis to laboratory-confirmed cases and 
is more clinically relevant.
National UK emergency department standards mean 
that patients must either be admitted or discharged 
within four hours to avoid financial penalty. This means 
that our patients had to have a sufficiently high stool 
frequency to produce a sample within this timeframe. 
Many of those requiring admission for rehydration were 
unable to produce a sample in hospital. Our sampling 
percentage is consistent with other similar surveillance 
studies [15-17]. The vaccine used in the UK (Rotarix) is 
a live attenuated form of one of the most commonly 
circulating human RV strains (G1P8). Although the PCR 
test used in this study could not distinguish wild-type 
virus from the vaccine strain, there were only three pos-
itive samples from children old enough to have been 
eligible for the vaccine. A limitation of our study is that 
since the project start date was after the beginning of 
Figure 4
Age distribution of all-cause gastroenteritis admissions < 18 years of age, Bristol Royal Hospital for Children, United 
Kingdom, 2012–2014 
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the first seasonal epidemic, the first seven weeks of 
data were collected retrospectively.
As can be seen from the differences between 2012 
and 2013, RV epidemics vary in size between years 
even in the absence of immunisation. It has recently 
been reported that 2014 was an exceptionally low RV 
year in both France and the Netherlands [18], despite 
neither country routinely using a RV vaccine. Although 
it is possible that the UK’s 2014 epidemic was also 
unusually small coincidentally to the commencement 
of vaccination, we feel it is unlikely that the entire 
effect observed effect is due to this. Case–control 
studies have shown that both licensed RV vaccines 
provide excellent direct protection in industrialised 
countries [19,20] with evidence of herd protection [21]. 
Mathematical models predict that after the introduc-
tion of RV vaccine there will be an increased average 
age of cases and a delay in the seasonal peak [22] [23]. 
With widespread vaccination removing the majority of 
susceptible patients, a ‘honeymoon period’ of very low 
disease incidence shortly after the introduction is also 
expected. But with the gradual accumulation of an un-
vaccinated naive fraction, at some point there may be 
a rebound rise in cases. Key variables that determine 
the timing of this phenomenon include vaccine uptake 
and consistency in coverage over time and place, dura-
tion of vaccine-induced protection, and the transmis-
sibility of the infection. The reduced number of cases 
seen in children too old to have been vaccinated is 
unexpected; it is not possible to discern whether this 
is evidence of herd effect or represents the true size 
of the underlying 2014 UK seasonal epidemic. For rea-
sons unknown, rotavirus epidemiology appears to 
have changed abruptly in the Netherlands, but in the 
absence of clinical disease (or vaccination), suscep-
tible patients will continue to accumulate creating a 
population susceptible to future outbreaks. To date 
this has not been reported in 2015 [24].
The United States (US) introduced a pentavalent RV 
vaccine (RotaTeq- SMSD) in 2006 and, with 50–60% 
vaccine coverage, a dramatic reduction in cases was 
observed the following season [25]. After a resurgence 
of disease in year two, cases have subsequently oscil-
lated in number biennially, cycling between 60% and 
80% lower than the pre-vaccine baseline [26]. These 
dynamics may be due to the suboptimal vaccine 
uptake, which in 2013 was still only 72.6%, 10% lower 
than other primary vaccines [27]. In 2006, Belgium 
was the first European country to introduce the same 
vaccine as the UK (Rotarix) and rapidly achieved vac-
cination coverage > 90% [19]. To date only three years’ 
post-introduction data have been published, with no 
rebound yet reported [28]. Public Health England have 
reported UK RV vaccine coverage rates of 93% first 
dose and 88% complete course and a 67% reduction 
in RV laboratory reports compared with a ten year aver-
age [29]. Our local RV vaccination rates were similar, 
91% first dose and 86% completed course. With a dif-
ferent vaccine at higher coverage rates than the US, the 
UK’s eventual epidemiology is likely to be more similar 
to Belgium. Ongoing surveillance will be important not 
only to track any rebound but also because the mono-
valent vaccine (Rotarix) has relatively lower efficacy 
against non G1 strains of virus [30,31] and may result 
in their relative emergence as overall RV circulation 
declines. However natural year-to-year genotype fluc-
tuations make interpretation of such ecology challeng-
ing. After Brazil introduced the monovalent vaccine, a 
three year progressive rise in G2P4 (89,93,100%) was 
followed by a sudden return of G1P8 (68%) in 2009, 
with non-vaccine genotypes predominating subse-
quently on a background of sustained public health 
benefits with significant reductions in gastroenteritis 
attendances, admissions and deaths [32].
The UK health economic analysis [33] estimated that 
RV was responsible for 9.3 emergency department con-
sultations and 4.5 admissions per 1,000 children under 
the age of five years and predicted secondary care sav-
ings of £7.4 (€10.4) million with the use of RV vaccine, 
almost exactly the same as our findings. The impact on 
primary care is not yet known, but any reduction in the 
estimated 100,000–150,000 annual consultations due 
to RV [33] will have had wider benefits by allowing oth-
ers to access pressured services. However, while the 
prevention of healthcare utilisation is important, the 
additional benefits of this vaccine to society at large 
may have been much greater by sparing children an 
unpleasant disease, sparing families time missed from 
productive work while caring for them and by prevent-
ing associated secondary cases.
Just one season after vaccine introduction, it is too 
early to conclude that our data entirely reflect vaccine 
effectiveness rather than epidemiological happen-
stance. But they provide a first description of remark-
able trends which will need to be followed closely over 
the seasons to come.
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